EB-Plate Is the First Completely Reusable 3D Cell Culture Microplate Launched by eNUVIO

What To Know

  • eNUVIO's completely reusable EB-Plate comes to the market at the right time as the demand for 3D cell culture microplates is high, conventional plastic plates are currently in short supply, and the zero-waste movement is becoming increasingly popular in laboratories.
  • “The first step in a new direction is always hard to take, and the EB-Plate finally gives research labs the ability to make a green choice when it comes to embryoid and spheroid generation.

December 8, 2020

EB-Plate, is the first completely reusable 3D cell culture microplate on the market. Scientific research currently consumes high-volumes of single-use plastics – from serological pipettes and pipette tips to vials and culture microplates – these are just a few of the many plastic items thrown in the garbage in labs every day.

eNUVIO’s completely reusable EB-Plate comes to the market at the right time as the demand for 3D cell culture microplates is high, conventional plastic plates are currently in short supply, and the zero-waste movement is becoming increasingly popular in laboratories. As with many emerging environmentally friendly options, it’s no surprise that the reusable and virtually indestructible EB-Plate comes in at a higher cost compared to its plastic counterparts. According to the company, the new plates pay for themselves after approximately 5-8 uses, and can be reused many times more.

eNUVIO* understands the hesitation to switch from tried-and-true devices to new tools, but asserts that in the case of the EB-Plate, scientists don’t have to compromise quality when switching from conventional single-use microplates to a greener choice. This new plate allows researchers to generate embryoid bodies, the necessary first step to growing larger self-assembled 3D cultures known as spheroids or organoids from stem cells. Owing to the unique geometry of each microwell, uniformly-sized spheroids can be generated with high reproducibility, and the high-transmissive plate bottom enables high-quality optical observation. The company anticipates that researchers will benefit from this environmentally-friendly device for a long time, both scientifically and economically.

3D cell cultures are quickly emerging as the next generation tools of choice for safety pharmacology and drug screening purposes. As such, conventional single-use plastic 3D cell culture microplates are increasingly being used in CROs, biotech and pharmaceutical companies as well as for fundamental research in academic and government laboratories. eNUVIO opens the door to researchers around the world to access the first, completely reusable and environmentally-friendly 3D cell culture microplate on the market. The company is banking on labs embracing greener choices in their workflows, and is working to expand their environmentally-friendly product offerings.

EB-PLATE Specifications:

  • 96 microwells/plate
  • Microplate outer dimensions: 127.7 x 85.4 mm
  • Chamber material: Polydimethylsiloxane (PDMS), biologically inert, non-degradable
  • Microplate height (w/o lid): 14.2 mm
  • Microwell opening diameter: 6 mm
  • Microwell diameter at base: 900 µm
  • Microplate bottom thickness: 1 mm
  • Chamber volume: 250 µl
  • Chamber pitch: 9 mm
  • Shipped sterile, ultra-low attachment (ULA) surface
  • In-house production ensures high quality at all times
  • Sold directly through enuvio.com or via scienceexchange.com


“The first step in a new direction is always hard to take, and the EB-Plate finally gives research labs the ability to make a green choice when it comes to embryoid and spheroid generation. There are basically no other green options on the market”, says Mark Aurousseau, CSO and co-founder of eNUVIO, Montreal, Canada.
He continues: “I’ve spoken to many scientists that sometimes just want to use a couple of wells of a plate for an experiment since reagents for this type of research can be quite expensive. They find themselves feeling horrible when they have no option but to throw out a half unused plate.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy